| Indian Immunologicals Ltd (IIL), the wholly owned subsidiary of the National Dairy Development Board (NDDB), opened its state-of-the-art human vaccines plant and research & development (R&D) centre in Hyderabad on Friday. The complex is set up with an investment of Rs 58 crore.
|
| |
| The plant will manufacture various human vaccines such as recombinant hepatitis B, measles, diphtheria, pertussis and tetanus. In addition, the plant has the capability to produce new combination vaccines.
|
| |
| It can simultaneously manufacture 200 million doses of each vaccine per annum. Amrita Patel, chairman, NDDB, said: “This plant marks a major milestone in indigenous technology development and places India on the global map in modern vaccine technology. We are committed to producing world class vaccines and making it available at affordable prices.”
|
| |
| The vaccines produced in this plant will also be exported to meet the growing demand for quality vaccines under UNICEF’s vaccine procurement programme. IIL already exports its veterinary vaccines to a number of countries and is the largest supplier of FMD vaccines to the Food & Agriculture Organisation (FAO).
|
| |
| “The global market for human & animal vaccines is worth about $8 billion and is growing at 9 per cent per annum. IIL aims to be a major vaccine player in both animal and humane vaccines and plans to garner a significant share of the global market,” an NDDB official said.
|
| |
| Set up with an investment of Rs 8 crore, the R&D center will develop various animal and human vaccines and biologicals. “Indian immunologicals will undertake research for low-cost and thermostable products that do not require a cold chain. A DNA rabies vaccine is being developed in collaboration with the Indian Institute of Science,” Patel added. |
| |
Content Guide
